PFG
JAZZ icon

Piershale Financial Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Piershale Financial Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.24K Hold
10
– – ﹤0.01% 241
2023
Q1 		$1.46K Hold
10
– – ﹤0.01% 261
2022
Q4 		$1.59K Buy
+10
New +$1.47K ﹤0.01% 258

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Piershale Financial Group's JAZZ Position: Q2 2023 in Review

Piershale Financial Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2023 at 10 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #241.

Piershale Financial Group first reported a position in JAZZ in Q4 2022 and has held it in 3 quarters since. The position peaked at $1.59K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

  • Piershale Financial Group held 10 shares of Jazz Pharmaceuticals worth $1.24K as of Q2 2023.
  • Piershale Financial Group left its Jazz Pharmaceuticals share count unchanged in Q2 2023.
  • Jazz Pharmaceuticals made up ﹤0.01% of Piershale Financial Group's portfolio in Q2 2023, its #241 holding.
  • Piershale Financial Group first reported a position in Jazz Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • Piershale Financial Group's Jazz Pharmaceuticals position peaked at $1.59K in Q4 2022.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.